We are live on ! Find out more
RA

Royce & Associates Portfolio holdings

AUM $12.4B
1-Year Est. Return 64.17%
This Fund
S&P 500
This Quarter Est. Return
+1.43%
1 Year Est. Return
+64.17%
3 Year Est. Return
+130.04%
5 Year Est. Return
+162.55%
10 Year Est. Return
+785.5%
AUM
$10.8B
AUM Growth
-$261M
Cap. Flow
-$202M
Cap. Flow %
-1.87%
Top 10 Hldgs %
9.55%
Holding
1,226
New
73
Increased
457
Reduced
388
Closed
76

Top Buys

Rank Stock Value
1
VIRT icon
Virtu Financial
VIRT
+$33.4M
2
MLAB icon
Mesa Laboratories
MLAB
+$27.4M
3
TNC icon
Tennant Co
TNC
+$19.8M
4
KWR icon
Quaker Houghton
KWR
+$18.2M
5
HLI icon
Houlihan Lokey
HLI
+$17.9M

Sector Composition

Rank Sector Weight
1 Industrials 28.27%
2 Technology 17.79%
3 Financials 14.2%
4 Consumer Discretionary 12.75%
5 Materials 8.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CUB
576
DELISTED
Cubic Corporation
CUB
$3.45M 0.03%
49,000
+6,000
+14% +$411K
FIVN icon
577
FIVE9
FIVN
$2.47B
$3.45M 0.03%
64,116
-55,500
-46% -$3.12M
TBNK
578
DELISTED
Territorial Bancorp Inc.
TBNK
$3.44M 0.03%
120,200
+35,100
+41% +$1M
CAMT icon
579
Camtek
CAMT
$6.28B
$3.43M 0.03%
365,600
+126,100
+53% +$1.15M
AMAG
580
DELISTED
AMAG Pharmaceuticals
AMAG
$3.42M 0.03%
295,798
-263,509
-47% -$2.77M
LITE icon
581
Lumentum
LITE
$75.3B
$3.37M 0.03%
63,000
BE icon
582
Bloom Energy
BE
$76.4B
$3.36M 0.03%
1,033,074
+172,673
+20% +$1.29M
CCU icon
583
Compañía de Cervecerías Unidas
CCU
$2.09B
$3.34M 0.03%
150,597
EGRX
584
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3.32M 0.03%
58,767
-8,866
-13% -$499K
BLFS icon
585
BioLife Solutions
BLFS
$1.78B
$3.27M 0.03%
196,655
+10,000
+5% +$188K
PFNX
586
DELISTED
Pfenex Inc.
PFNX
$3.27M 0.03%
386,890
+57,300
+17% +$415K
GBDC icon
587
Golub Capital BDC
GBDC
$3.23B
$3.26M 0.03%
+176,429
New +$3.17M
PETQ
588
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
$3.25M 0.03%
119,305
+16,535
+16% +$523K
CSSE
589
DELISTED
Chicken Soup for the Soul Entertainment, Inc. Class A Common Stock
CSSE
$3.25M 0.03%
334,500
+20,000
+6% +$178K
SCOR icon
590
Comscore
SCOR
$78.7M
$3.24M 0.03%
84,920
+16,062
+23% +$927K
GBL
591
DELISTED
GAMCO Investors, Inc.
GBL
$3.23M 0.03%
165,446
SLAB icon
592
Silicon Laboratories
SLAB
$7.34B
$3.23M 0.03%
29,000
XEC
593
DELISTED
CIMAREX ENERGY CO
XEC
$3.23M 0.03%
67,300
LPSN
594
DELISTED
LivePerson
LPSN
$3.21M 0.03%
6,000
ITGR icon
595
Integer Holdings
ITGR
$4.29B
$3.2M 0.03%
42,400
UTMD icon
596
Utah Medical Products
UTMD
$238M
$3.19M 0.03%
33,318
+71
+0.2% +$6.6K
NXST icon
597
Nexstar Media Group
NXST
$5.2B
$3.18M 0.03%
31,060
+4,800
+18% +$486K
MCRN
598
DELISTED
Milacron Holdings Corp.
MCRN
$3.18M 0.03%
190,556
-727,172
-79% -$11.7M
APYX icon
599
Apyx Medical
APYX
$125M
$3.15M 0.03%
465,915
+113,400
+32% +$805K
PVG
600
DELISTED
PRETIUM RESOURCES INC.
PVG
$3.12M 0.03%
270,701

Similar funds

Royce & Associates's Q3 2019 Portfolio in Review

As of Q3 2019, Royce & Associates held 1,226 positions worth $10.8B, down 2.4% from $11.1B the previous quarter. Its ten largest holdings account for 9.6% of the portfolio.

Royce & Associates's Q3 2019 filing shows 73 new, 457 increased, 388 reduced and 76 closed positions. Its largest new stake was Upbound Group: 521,616 shares worth $13.5M. The largest sale was John B. Sanfilippo & Son, an estimated $73.8M.

By sector, the portfolio is most concentrated in Industrials at 28% of assets, down from 29% a quarter earlier, followed by Technology and Financials.

  • Royce & Associates's largest Q3 2019 buy was Upbound Group: 521,616 shares worth $13.5M.
  • Royce & Associates added most to Virtu Financial in Q3 2019, an estimated $33.4M increase.
  • Royce & Associates's biggest Q3 2019 reduction was John B. Sanfilippo & Son, cutting an estimated $73.8M.
  • Royce & Associates fully exited Cambrex Corporation in Q3 2019, selling an estimated $14.7M.
  • Royce & Associates's ten largest holdings make up 9.6% of its $10.8B portfolio in Q3 2019.
  • Royce & Associates opened 73 new positions and closed 76 in Q3 2019.
  • Royce & Associates's portfolio value fell 2.4% quarter-over-quarter to $10.8B.

Based on Royce & Associates's 13F filing for Q3 2019, filed 13 Nov 2019.